ClinicalTrials.gg

Program

fetrastobart vedotin

In Pfizer's pipeline, PD-L1-directed antibody-drug conjugate. Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Pfizer.

Furthest: phase 3, since Aug 20, 20252 company-led studies, 2 open or runningNext primary completion: Jan 5, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer22 open or runningphase 3since Aug 20, 2025Dec 15, 2021Jan 5, 2028phase 1 · NCT05208762
  • Named in Pfizer’s own pipeline as fetrastobart vedotin PF-08046054, phase 3, as of Nov 3, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 15, 2021First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT05208762 · 714 planned · United States, Belgium, Canada and more
  2. Aug 20, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07144280 · 680 planned · United States, Argentina, Australia and more

Ahead

  1. Jan 5, 2028Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT05208762
  2. Mar 10, 2028Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT07144280

TargetBeta

“PD-L1-directed antibody-drug conjugate”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of fetrastobart, an antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), conjugated to the cytotoxic agent monomethyl auristatin E (MMAE) via a protease-cleavable peptide l…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of fetrastobart, an antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), ”NCIt, by rule

Other programs on CD274

ProgramCompanyFurthest phaseStudies
durvalumabruleAstraZenecaphase 4102
adebrelimabruleJiangsu HengRui Medicinephase 351
pumitamigBioNTechphase 334
benmelstobartruleSino Biopharmaceuticalphase 333
retlirafusp alfaruleJiangsu HengRui Medicinephase 320
Anti-PD-L1 Antibody-drug Conjugate HLX43Fosun Pharmaphase 317
erfonrilimabruleAlphamab Oncologyphase 314
Anti-PD-L1/4-1BB Bispecific Antibody LBL-024rulenanjing-leads-biolabs-co-ltdphase 310
socazolimabruleLee's Pharmaceuticalphase 39
acasunlimabruleGenmabphase 36
sotiburafusp alfarulehuabo-biopharm-co-ltdphase 35
HLX37Fosun Pharmaphase 32

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07144280Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3RecruitingMar 10, 2028680
NCT05208762Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more1RecruitingJan 5, 2028714

How it is read

Names in the registry

  • “PF-08046054”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.